Rivaroxaban: all 303 studies that test it
Page 2 of 4. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- Oral Rivaroxaban in Children With Venous ThrombosisCompletedNCT01684423Phase 2Results posted
- Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionCompletedNCT01674647Phase 3Results posted
- Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee ArthroscopyCompletedNCT01629381Phase 2Results posted
- Switching Study From Warfarin to RivaroxabanCompletedNCT01507051Phase 1Results posted
- Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus FondaparinuxCompletedNCT01499953Phase 3Results posted
- Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet RivaroxabanCompletedNCT01436526Phase 1Results posted
- Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee ReplacementCompletedNCT01094886Phase 3Results posted
- An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary SyndromeCompletedNCT00809965Phase 3Results posted
- Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 InducerCompletedNCT00786422Phase 2Results posted
- Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill PatientsCompletedNCT00571649Phase 3Results posted
- Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedNCT00494871Phase 3Results posted
- Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT StudyCompletedNCT00440193Phase 3Results posted
- Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE StudyCompletedNCT00439777Phase 3Results posted
- Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension StudyCompletedNCT00439725Phase 3Results posted
- An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial FibrillationCompletedNCT00403767Phase 3Results posted
- Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)CompletedNCT00402597Phase 2Results posted
- Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.CompletedNCT00362232Phase 3Results posted
- Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed ConditionsCompletedNCT07807488Phase 1
- Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser AblationCompletedNCT07699796Phase 4
- Rivaroxaban in Pediatric Patients With DVTCompletedNCT07618988Phase 4
- Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous ThrombosisCompletedNCT07523347Not applicable
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy ParticipantsCompletedNCT07312851Phase 1
- COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSISCompletedNCT07077954Phase 1
- Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular DiseasesCompletedNCT06986369Phase 4
- Bioequivalence Study of Rivaroxaban 10 mg Film-coated TabletsCompletedNCT06558058Phase 1
- Bioequivalence Study of Rivaroxaban 20 mg Film-coated TabletsCompletedNCT06558045Phase 1
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)Active, not recruitingNCT06449469Not applicable
- Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral AnticoagulantCompletedNCT06372483Phase 1
- Rivaroxaban Sotorasib Interaction StudyCompletedNCT06314763Phase 4
- Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque InflammationCompletedNCT05797376Phase 4
- Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon AngioplastyCompletedNCT05750758Not applicable
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy VolunteersCompletedNCT05723510Phase 1
- Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMICompletedNCT05705089Phase 3
- Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage OcclusionStatus unknownNCT05671276Phase 4
- To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary SyndromeStatus unknownNCT05573958Phase 4
- Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen OvaleCompletedNCT05546320Phase 2
- Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic EventsCompletedNCT05515120Phase 2/3
- Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants SubjectsStatus unknownNCT05491460Phase 1
- Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular RevascularizationStatus unknownNCT05308030Early Phase 1
- Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal CancerStatus unknownNCT05303818Phase 4
- Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft SurgeryStatus unknownNCT05300555Phase 4
- Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery EctasiaStatus unknownNCT05233124Phase 2
- Trained Immunity by Dual-pathway Inhibition in Coronary Artery DiseaseStatus unknownNCT05210725Phase 4
- A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091CompletedNCT05128591Phase 1
- Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIFCompletedNCT05077683Phase 3
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisActive, not recruitingNCT05047172Phase 3
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve ImplantationCompletedNCT05035277Phase 3
- THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)TerminatedNCT05033314Phase 3
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery DiseaseCompletedNCT05009862Phase 4
- Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs EnoxaparinStatus unknownNCT04999176Phase 3
- Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial DiseaseStatus unknownNCT04994223Early Phase 1
- Rivaroxaban in Left Ventricular ThrombusCompletedNCT04970576Phase 4
- Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein ThrombosisStatus unknownNCT04967573Phase 3
- Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD PatientsCompletedNCT04853719Phase 4
- Rivaroxaban in Type 2 Myocardial InfarctionsCompletedNCT04838808Phase 2/3
- Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.CompletedNCT04767776Phase 1
- COVID-19 Antithrombotic Rivaroxaban EvaluationTerminatedNCT04757857Phase 4
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting ConditionsStatus unknownNCT04753489Phase 1
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed ConditionsStatus unknownNCT04729998Phase 1
- A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy MenCompletedNCT04727021Phase 1
- A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male ParticipantsCompletedNCT04720092Phase 1
- Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19Status unknownNCT04715295Phase 4
- Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed ConditionsCompletedNCT04689919Phase 1
- Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE TrialCompletedNCT04662684Phase 3
- Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)CompletedNCT04640181Phase 2
- Rivaroxaban vs. Warfarin in CVT TreatmentCompletedNCT04569279Phase 3
- Postoperative Thrombosis Prevention in Patients With CDActive, not recruitingNCT04486859Not applicable
- Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese VolunteersCompletedNCT04424381Phase 1
- Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19TerminatedNCT04416048Phase 2
- Anticoagulation Therapy After Splenectomy in Cirrhosis PatientCompletedNCT04397289Phase 1/2
- Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION TrialCompletedNCT04394377Phase 4
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Status unknownNCT04351724Phase 2/3
- Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TerminatedNCT04333407Not applicable
- Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialCompletedNCT04324463Phase 3
- Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access PortsStatus unknownNCT04309240Phase 3
- Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)CompletedNCT04273516Phase 2/3
- Prophylactic Anticoagulation for Catheter-related ThrombosisStatus unknownNCT04256525Phase 4
- DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery DiseaseCompletedNCT04218656Phase 4
- Pharmacokinetics of Rivaroxaban After Bariatric SurgeryCompletedNCT04180436Phase 1
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs RivaroxabanStatus unknownNCT04169269Phase 4
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic DiseaseCompletedNCT04142125Phase 3
- Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAOStatus unknownNCT04135677Phase 4
- AntiCoagulants and COGnitionStatus unknownNCT04073316Phase 4
- Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin TherapyStatus unknownNCT04059679Phase 4
- DOAC Versus VKA After Cardiac SurgeryWithdrawnNCT04002011Phase 2
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial FibrillationCompletedNCT03996772Phase 3
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney DiseaseCompletedNCT03969953Phase 3
- Comparative Study of Oral Anticoagulation in Left Ventricular ThrombiCompletedNCT03926780Phase 3
- RIvoraxaban in Mitral StenosisTerminatedNCT03926156Phase 3
- Oral Anticoagulation in HemodialysisCompletedNCT03799822Phase 4
- A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial FibrillationStatus unknownNCT03792152Not applicable
- Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)Status unknownNCT03786757Phase 3
- Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACSStatus unknownNCT03775746Phase 4
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized AnticoagulantStatus unknownNCT03764241Phase 3
- Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial FibrillationCompletedNCT03749057Phase 4
- Efficacy Comparison of Warfarin Versus Rivaroxaban CVTStatus unknownNCT03747081Phase 1/2
- RIvaroxaban for Stroke Patients With AntiPhospholipid SyndromeCompletedNCT03684564Phase 2
- Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist WarfarinWithdrawnNCT03673605Phase 4
- Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery OcclusionTerminatedNCT03630055Phase 3
- Surgical Revascularization Outcomes After Oral Anticoagulation or AntiplateletsStatus unknownNCT03605433Phase 3